Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.

ABSTRACT:

Background

The cyclin-dependent-kinase inhibitors (CDKN)/retinoblastoma (RB1) pathway has been implicated as having a role in medullary thyroid carcinoma (MTC) tumorigenesis. CDKN2C loss has been associated with RET-mediated MTC in humans but with minimal phenotypic correlation provided. The objective of this study was to evaluate the association between tumor RET mutation status, CDKN2C loss, and aggressiveness of MTC in a cohort of patients with sporadic disease.

Methods

Tumors from patients with sporadic MTC treated at a single institution were evaluated for somatic RET^M918T mutation and CDKN2C copy number loss. These variables were compared to patient demographics, pathology detail, clinical course, and disease-specific and overall survival.

Results

Six

SUBMITTER: Grubbs EG 

PROVIDER: S-EPMC6453497 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature